Summary
McKesson Corporation (MCK) announced a board composition change through an 8-K filing. The company has elected Deborah Dunsire, M.D., to its Board of Directors, effective June 3, 2024. Dr. Dunsire brings extensive experience in the biopharmaceutical and oncology sectors, having previously served as CEO of H. Lundbeck A/S and holding various leadership roles in other pharmaceutical companies. Her appointment is expected to enhance the Board's expertise in relevant industries. In addition, McKesson disclosed that two current directors, Linda Mantia and Susan R. Salka, will not be standing for re-election at the upcoming 2024 annual meeting of shareholders. Their terms will expire at that meeting. These changes signal a refresh in the Board's composition, bringing in new strategic perspectives while transitioning out existing members.
Key Highlights
- 1Election of Deborah Dunsire, M.D., to the Board of Directors, effective June 3, 2024.
- 2Appointment of Dr. Dunsire to the Compensation and Talent Committee and Finance Committee.
- 3Dr. Dunsire possesses over 30 years of leadership experience in the biopharmaceutical, oncology, and specialty industries.
- 4Prior experience of Dr. Dunsire includes serving as CEO of H. Lundbeck A/S and executive roles at other major pharmaceutical firms.
- 5Linda Mantia will not be standing for re-election at the 2024 annual meeting.
- 6Susan R. Salka will not be standing for re-election at the 2024 annual meeting.
- 7The company issued a news release on June 3, 2024, to announce these board changes.